CT scan

Global Flat Panel Detector (FPD) based X-Ray for Cone Beam Computed Tomography (CBCT) Market Trajectory & Analytics Report 2021 - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:26am

b'The "Flat Panel Detector (FPD) based X-Ray for Cone Beam Computed Tomography (CBCT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com\'s offering.\nAmid the COVID-19 crisis, the global market for Flat Panel Detector (FPD) based X-Ray for Cone Beam Computed Tomography (CBCT) estimated at US$2.2 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.\nOrthopedics, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$2.3 Billion by the end of the analysis period.

Key Points: 
  • b'The "Flat Panel Detector (FPD) based X-Ray for Cone Beam Computed Tomography (CBCT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com\'s offering.\nAmid the COVID-19 crisis, the global market for Flat Panel Detector (FPD) based X-Ray for Cone Beam Computed Tomography (CBCT) estimated at US$2.2 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.\nOrthopedics, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$2.3 Billion by the end of the analysis period.
  • After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dental segment is readjusted to a revised 7.6% CAGR for the next 7-year period.\nThe U.S. Market is Estimated at $603.9 Million, While China is Forecast to Grow at 10.4% CAGR\nThe Flat Panel Detector (FPD) based X-Ray for Cone Beam Computed Tomography (CBCT) market in the U.S. is estimated at US$603.9 Million in the year 2020.
  • Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.\nIn the global ENT segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$484.4 Million by the year 2027, while Latin America will expand at a 8.5% CAGR through the analysis period.\n'

Paragon 28, Inc. Receives FDA Clearance and Successfully Completes First MAVEN™ Patient-Specific Instrumentation Surgery

Tuesday, May 4, 2021 - 9:55pm

MAVEN PSI is compatible with both weight-bearing CT and traditional CT scanning technologies and features one continuous scan from the knee through the base of the foot to capture biomechanically accurate data.

Key Points: 
  • MAVEN PSI is compatible with both weight-bearing CT and traditional CT scanning technologies and features one continuous scan from the knee through the base of the foot to capture biomechanically accurate data.
  • The System introduces a perfect blend of performance and reliability.
  • MAVEN PSI also allows for refined intra-operative positioning and micro adjustments if necessary.
  • With this comprehensive portfolio, Paragon 28 provides its customers innovative ankle solutions for trauma, arthritis, and limbsalvage.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/paragon-28-inc-receives-fda-clea...\n'

Accuray Receives Shonin Approval for ClearRT™ Helical kVCT Imaging, CE Mark Expected by End of June; Expands Commercial Launch

Thursday, April 22, 2021 - 12:30pm

The team has more than 18 years\' experience treating patients with the TomoTherapy System and recently upgraded to the Radixact System, the next-generation TomoTherapy platform.

Key Points: 
  • The team has more than 18 years\' experience treating patients with the TomoTherapy System and recently upgraded to the Radixact System, the next-generation TomoTherapy platform.
  • The ClearRT daily targeting images exceeded our expectations, and provided noticeably superior image quality compared to more traditional cone-beam CT available on conventional linear accelerators.
  • The imaging technology will now be available in Japan and the U.S. ClearRT imaging is expected to be accessible to EU customers following receipt of the CE Mark.
  • "\n*ClearRTHelical kVCT Imaging for the RadixactTreatment Delivery System is not available for sale in all markets.

RSNA: Lung Cancer Screening Predicts Risk of Death from Heart Disease

Thursday, April 15, 2021 - 3:00pm

b'OAK BROOK, Ill., April 15, 2021 /PRNewswire-PRWeb/ --A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a study published in Radiology: Cardiothoracic Imaging .\nCardiovascular disease is the leading cause of mortality worldwide.

Key Points: 
  • b'OAK BROOK, Ill., April 15, 2021 /PRNewswire-PRWeb/ --A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a study published in Radiology: Cardiothoracic Imaging .\nCardiovascular disease is the leading cause of mortality worldwide.
  • It even outpaces lung cancer as the leading cause of death in heavy smokers.\nLow-dose CT lung scans are used to screen for lung cancer in high-risk people such as heavy smokers.
  • These CT scans also provide an opportunity to screen for cardiovascular disease by extracting information about calcification in the heart and aorta.
  • The Society is based in Oak Brook, Ill. ( RSNA.org )\nFor patient-friendly information on lung cancer screening, visit RadiologyInfo.org .\nLinda Brooks, Radiological Society of North Aurora, 630-590-7762, lbrooks@rsna.org\n'

SenseTime Receives CE Mark for its AI Medical Solution SenseCare-Chest DR Pro Diagnostic Software

Thursday, April 8, 2021 - 8:00am

ABU DHABI, UAE, April 8, 2021 /PRNewswire/ --SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro.

Key Points: 
  • ABU DHABI, UAE, April 8, 2021 /PRNewswire/ --SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro.
  • The certification of SenseCare-Chest DR Pro marks another milestone for SenseTime in introducing its AI medical solutions for both computed tomography (CT) and digital radiography (DR) to international markets after its SenseCare-Lung Pro medical solution was granted the CE mark last year.
  • It means that SenseTime's AI medical solutions can provide comprehensive support with an international standard to medical institutions around the world for chest diseases based on CT and DR imaging modalities.
  • To assist medical professionals conducting CXR, the SenseCare-Chest DR Pro was developed based on SenseTime's proprietary deep-learning technologies.

Philips SmartCT 3D image acquisition, visualization and measurement software for its Azurion Image Guided Therapy System receives FDA 510(k) clearance

Tuesday, April 6, 2021 - 2:00pm

SmartCT is a key component of Philips Image Guided Therapy System Azurion providing interventionalists with CT-like 3D images (Cone Beam CT) to support diagnosis, therapy planning, treatment and follow-up for interventional radiology procedures.

Key Points: 
  • SmartCT is a key component of Philips Image Guided Therapy System Azurion providing interventionalists with CT-like 3D images (Cone Beam CT) to support diagnosis, therapy planning, treatment and follow-up for interventional radiology procedures.
  • SmartCT brings total control of the Azurion platform to a touchscreen tablet situated alongside the interventional radiology table.
  • With SmartCT, users are guided through the image acquisition process and can review and interact with the acquired CT-like 3D images on the systems table-side touch screen module using 3D visualization and measurement tools.
  • Philips SmartCT image acquisition, visualization and measurement software is an integral part of the next-generation Philips Image Guided Therapy System Azurion which was launched in September 2020, marking an important step forward in optimizing clinical and operational lab performance and expanding the role of image-guided interventions in the treatment of patients.

Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial ahead of Planned Commercial Test

Wednesday, March 31, 2021 - 1:00pm

Based on recently published USPSTF guidelines1, annual lung cancer screening by low-dose CT scan is recommended for 15 million U.S. adults.

Key Points: 
  • Based on recently published USPSTF guidelines1, annual lung cancer screening by low-dose CT scan is recommended for 15 million U.S. adults.
  • An affordable, high performance, broadly available blood test could help increase screening rates and reduce overall lung cancer mortality."
  • Under the partnership, Delfi's test will be studied to potentially increase the number of individuals who are eligible for lung cancer screening.
  • The challenges of implementing low-dose computed tomography for lung cancer screening in low- and middle-income countries.

Smiths Detection to supply checkpoint security screening equipment to Kuwait International Airport

Friday, March 26, 2021 - 7:00am

Smiths Detection, a leading threat detection and security technology company, will supply a full suite of passenger baggage screening equipment for Kuwaits new International Airport Terminal 2, which is currently under construction.

Key Points: 
  • Smiths Detection, a leading threat detection and security technology company, will supply a full suite of passenger baggage screening equipment for Kuwaits new International Airport Terminal 2, which is currently under construction.
  • Smiths Detections leading-edge technology will help ensure the quick and thorough screening of passengers passing through the terminal.
  • About the Smiths Detection equipment selected:
    HI-SCAN 6040 CTiX Offers advanced screening of carry-on baggage using Computed Tomography (CT).
  • Smiths Detection, part of Smiths Group, is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence.

RadSite Launches Dental and Medical Cone Beam CT Accreditation Programs

Tuesday, March 23, 2021 - 10:00am

ANNAPOLIS, Md., March 23, 2021 /PRNewswire-PRWeb/ -- RadSite, a leading accrediting organization promoting performance and quality-based imaging practices, announced today that it is offering two new accreditation programs for Cone Beam CT imaging suppliers, Dental and Medical.

Key Points: 
  • ANNAPOLIS, Md., March 23, 2021 /PRNewswire-PRWeb/ -- RadSite, a leading accrediting organization promoting performance and quality-based imaging practices, announced today that it is offering two new accreditation programs for Cone Beam CT imaging suppliers, Dental and Medical.
  • Dr. Harrell is the chair of RadSite's Cone Beam CT Standards Committee and Assistant Associate Professor at the University of Alabama, Birmingham.
  • He adds: "The Standards Committee spent many hours discussing key performance and practice parameters that Cone Beam CT imaging suppliers should adhere to."
  • The new Cone Beam CT Standards supplement RadSite's MAP ADI accreditation programs covering CT, MRI, and Nuclear Medicine (i.e., PET, PET/CT and SPECT) for imaging suppliers.

Global Contrast Agents/Media Market to 2027 - Increasing Demand for Diagnostic and Interventional Radiology Procedures Presents Opportunities - ResearchAndMarkets.com

Tuesday, March 16, 2021 - 11:18am

The "Contrast Agents/Media Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contrast Agents/Media Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.
  • Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents.
  • X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging).